Stocktoria
Travere Therapeutics, Inc. TVTX
Travere Therapeutics, Inc. (TVTX) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $490.7M at a -5.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.55 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-25 | Guggenheim | Buy (main) |
| 2026-06-22 | Wedbush | Outperform (main) |
| 2026-06-18 | Evercore ISI Group | Outperform (main) |
| 2026-06-15 | Citigroup | Buy (main) |
| 2026-06-12 | Wells Fargo | Overweight (main) |
| 2026-06-03 | Citigroup | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.459 |
| Retained earnings / assets | -2.433 |
| EBIT / assets | -0.104 |
| Equity / liabilities | 0.234 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | 5/9 | -5.38 | — | +110.5% |
| NATR | NATURES SUNSHINE PRODUCTS INC | 6/9 | 5.82 | 18.9 | +5.7% |
| BBIO | BridgeBio Pharma, Inc. | 1/9 | -14.22 | — | +126.3% |
| ZLAB | Zai Lab Ltd | 3/9 | -3.61 | — | +15.3% |
| MIRM | Mirum Pharmaceuticals, Inc. | 4/9 | 0.54 | — | +54.7% |
| HCM | HUTCHMED (China) Ltd | 4/9 | 6.45 | 31.3 | -13% |
| ORGO | Organogenesis Holdings Inc. | 3/9 | 5.27 | 8.4 | +17% |
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
FAQ
Is TVTX financially healthy?
Travere Therapeutics, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does TVTX pay a dividend?
No, Travere Therapeutics, Inc. does not currently pay a dividend.
How profitable is TVTX?
In FY2025, Travere Therapeutics, Inc. had a net margin of -5.2% and a return on equity of -22.2%.
What is the analyst price target for TVTX?
The average Wall-Street price target for Travere Therapeutics, Inc. is $58.36, about 6.1% below the recent price, from 14 analysts (consensus: strong buy).
Is TVTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Travere Therapeutics, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.